Company Overview - Tangji Medical Technology Co., Ltd. is a China-based medical device company focused on providing innovative solutions for the treatment and management of metabolic diseases, including obesity and type 2 diabetes [3] - The company's core product, GBS, is a minimally invasive medical device approved as a Class III innovative medical device in China, aimed at treating obesity [3][5] - As of February 2, 2026, the company has successfully developed and commercialized an EBMT treatment device and has received regulatory approval for two adjunct products and a digital health management platform [3][4] Financial Performance - For the fiscal year 2024, the company reported revenues of approximately RMB 12.709 million, with a gross profit of RMB 10.282 million [6][8] - Research and development costs for the same period were approximately RMB 41.126 million, leading to a pre-tax loss of RMB 65.957 million [7][8] Market Potential - The market for EBMT medical devices in China is expected to grow from RMB 12.7 million in 2024 to RMB 782.1 million by 2029, representing a compound annual growth rate (CAGR) of 128.0% [9] - The global DJBL medical device market is projected to expand from nearly zero growth in 2020-2023 to approximately USD 1.8 million in 2024, with a CAGR of 171.7% expected from 2024 to 2029 [11] Regulatory Approvals and Clinical Trials - The company is actively pursuing global expansion for GBS and has received regulatory approvals in eight countries, including Hong Kong and Indonesia [4] - GBS-SH, a product targeting MASH with obesity, received breakthrough device designation from the FDA, marking the company as the only Chinese firm to achieve this status as of the last feasible date [5] Board and Shareholding Structure - The board of directors consists of six members, including one executive director and three independent non-executive directors, with a term of three years [18] - The largest shareholder, Mr. Zuo, holds 28.96% of the company, controlling approximately 35.94% of the issued share capital through an employee shareholding platform [20]